Not admitted · Commitment (own venture)
Rules 1.1.0 · as of 14 Sep 2026
Rick Doblin · Said 26 Aug 2020 · doblin-0253
Quote
Commitment (own venture)
“And so now we're assuming two years that the second phase three study will be done by the middle of 2022. We're hoping to be approved before the end of 2022 or early 2023 assuming our data justifies that.”
Doblin dates the end of the second Phase 3 trial (MAPP2) to mid-2022 and FDA approval to late 2022 or early 2023.
The forecaster's own organization can make the outcome happen by its own decision: clinic openings, product launches, hires, trial starts, filings by their own company. Listed in the commitments table, never scored.